Cardiovascular Flashcards
Hypertension
Normal Blood pressure
- Systolic less than 120 and Diastolic less than 90
Hypertension Stage 1
- Systolic between 130-139 and Diastolic between 80-89
Hypertension Stage 2
- Systolic at least 140 OR a diastolic at least 90
Diagnosis:
- Ambulatory blood pressure monitoring (ABPM) is considered gold standard for diagnosing hypertension
- If the patient has one or more of the following criteria using ABPM, this indicated hypertension
1) Criteria include a 24 hour mean of either a systolic of 125 or greater OR a diastolic of 75 or greater
2) Day time or awake time mean of either a systolic of 130 or greater or a diastolic of 80 or greater
3) Night time or asleep time mean of either a systolic of 110 or greater or a diastolic of 65 or greater
ONLY circumstances where out of office confirmatory readings are NOT required
1) When a patient present with a hypertensive crisis (SBP 180 or greater or a DBP 120 or greater)
2) When a patient presents with a SBP of 160 or greater or a DNP of 100 or greater who also have known target end organ damage
Hypertension Treatment
Non-pharmacological treatment
- Dietary salt restriction, weight loss, exercise and limiting alcohol intake
Pharmacological treatment:
- First line agents:
- Angiotensin converting enzyme inhibitors (ACEI)
- Angiotensin II receptor blockers (ARBs)
- Calcium channel blockers (CCBs)
- Thiazide diuretics
Expert recommendations:
- Single drug therapy is unlikely to be successful in the treatment of hypertension if a patients blood pressure is more than 20/10 above the goal
- UpToDate recommends patients with a sBP of 140 or greater or a DBP of 90 or greater should be started on combination therapy
- First choice: ACE or ARB - Dihydropyridine CCB
- Thiazide preferred over CCB: patients with edema, osteoporosis or calcium nephrolithiasis
- Chlorthalidone or indapamide preferred over hydrochlorothiazide
Angiotensin Converting Enzyme Inhibitors (ACEIs)
- Used in the treatment of hypertension
- Preferred option in patients with chronic kidney disease and heart failure
Examples: Lisinopril, Benazepril, Captopril, Enalapril
Side effects: Related to either decreased angiotensin II or increased kinins
- Decreased angiotensin II
- Hypotension, acute kidney injury, hyperkalemia and pregnancy complications
- If hyperkalemia occurs and is unable to be managed or if creatinine increased >30% baseline, within the first 6-8 weeks, ACE termination should be considered.
- Increased Kinins
- Dry hacking cough, angioedema (rare but life threatening)
Important points
- Contraindicated in pregnancy
- ACE inhibitors and ARBs can NOT be taken together
Angiotensin II receptor blockers (ARBs)
- Used in the treatment of hypertension
- Preferred option in patients with chronic kidney disease and heart failure
Examples: Losartan, Valsartan, Candesartan
Side effects:
- Higher rates of hypotension symptoms compared to ACEIs
- ARBs are LESS likely than ACEIs to cause a cough and angioedema
Important points:
- Contraindicated in pregnancy
- ACEIs and ARBs can NOT be taken together
Hypertensive Medications in Pregnancy
“New Little Mama”
N - Nifedipine
L - Labetaolol
M - Methyldopa
Calcium Channel Blockers
- Can be used as monotherapy or adjunct
- Significant amount of data supporting CCBs reduction in subsequent cardiac events
- Metabolized through the CYP450 system
NON-Dihydropyridines
- Weaker vasodilator, works more to decrease the contractility of the heart
- Used for hypertensions (less frequently), chronic stable angina, cardiac arrhythmias
Examples: Verapamil and Diltiazem
Side effects: Constipation, bradycardia, decreased cardiac output, gingival hyperplasia
Dihydropyridines
- Potent vasodilators with minimal cardiac effects
- Used for hypertension or chronic stable angina
Examples: Amlodipine, Nifedipine, Nicardipine
Side effects
- Headache, lightheadedness, flushing, dependent peripheral edema, gingival hyperplasia
- Treat peripheral edema by reducing CCB dose, switching to a non-Dihydropyridines and/or add a RAS-block agent (ACE or ARB)
Thiazide Diuretics
- Thiazide like diuretics are more effective at treating hypertension and reducing cardiac events and mortality when compared to hydrochlorothiazide
Examples:
- Hydrochlorothiazide (HCTZ)
- Caution with elderly, Caucasian patients (increased risk of skin CA), renal or hepatic impairment, arrhythmias, diabetes mellitus, seizure disorder, history of gout, pancreatitis.
- Thiazide-like diuretics
- Chlorthalidone, indapamide
Side effects:
- Dose dependent side effects: Hypokalemia, hyponatremia, hypomagnesemia, hyperuricemia, hyperglycemia and hyperlipidemia
- Decreased risk of hypokalemia by:
- Maintaining low sodium diet
- Combining with an ACE or ARB
- Avoid combing HCTZ with a CCB as this may cause acquired neutropenia
- Non-dose dependent side effects: sleep disturbances and sexual dysfunction
Contraindications:
- Sulfa allergy and anuria
Alpha-1 Blockers
Examples: Terazosin, Tamsulosin, Alfuzosin, Silodosin
- Terazosin is useful for patients with benign prostatic hyperplasia (BPH)
Beta Blockers
Examples: Labetalol, Carvedilol, Propranolol, Nebivolol
- Labetaolol is drug of choice for pregnant patients with hypertension
- IF contraindicated, other options include methyldopa and nifedipine
Contraindications to Beta Blockers:
- Severe bradycardia, AV Block, 2nd-3rd degree, decompensated heart failure, sick sinus syndrome, asthma.
Complications of Hypertension
- Hypertension is considered the most significant, modifiable risk factor for cardiac disease
- Hypertension is associated with an increased risk of stroke, coronary artery disease, heart failure, atrial fibrillation, abdominal aortic aneurysm, and peripheral vascular disease.
Mild retinal microvascular changes
- Retinal arteriolar narrowing and arteriovenous nicking also referred to as “nipping”
Moderate retinal microvascular changes
- Hemorrhages, either flame or dot-shaped, cotton-wool spots, hard exudates, and micro aneurysms
Severe retinal microvascular changes
- all previous retinal changes PLUS papilledema (optic disc edema)
- Papilledema
- Consequence of intracranial hypertension
- Early symptoms: very brief episodes of vision loss, loss of spontaneous venous pulsations, optic disc is retained
- Late symptoms: Optic disc becomes elevated, the cup is completely destroyed, disc margins become obscured, edema extends into the retina, multiple flame hemorrhages and common wool spots.
Dyslipidemia
Abnormally elevated cholesterol or lipids and is a risk factor for atherosclerotic cardiovascular disease
Treatment:
- Statin therapy is first line
- Examples: Lovastatin, pravastatin, simvastatin, fluvastatin, Atorvastatin, Rosuvastatin
- Statins are contraindicated in pregnancy
Indications for a statin
- LDL-C >190
- LDL-C <190, the indication for statin therapy is dependent on their risk for a cardiac event in the next 10 years.
- Intermediate risk for cardiovascular disease
- 5 to 7.4% risk of a cardiac event within the next 10 years and a LDL of 100 to <190.
- Literature recommends to initiate a stating
- Discuss risk and benefits
- High to very high risk for cardiovascular disease
- >7.5% risk for a cardiac event in the next 10 years and a LDL 100 to <190
- Initiated moderate intensity statin
- Initiated high intensity statin if risk for cardiac event is >20%
Important points
- After starting a stain, it is recommended to measure the patients LDL-C response at 4-6 weeks after starting therapy and every 12 months thereafter
- The goal is to get the LDL < 100
- Statins are contraindicated in pregnancy
Statin Therapy (Low Intensity)
Lovastatin 20mg
Pravastatin 10 to 20mg
Simvastatin 10mg
Fluvastatin 20 to 40mg
Statin Therapy (Moderate Intensity)
Lovastatin 40 to 80mg
Pravastatin 40 to 80mg
Simvastatin 20 to 40mg
Atorvastatin 10 to 20mg
Rosuvastatin 5 to 10mg
Statin Therapy (High intensity)
Atorvastatin 40 to 80mg
Rosuvastatin 20 to 40mg
Cholesterol Levels
Desirable: <200
Borderline: 200 to 239
High Risk: >240
Triglycerides
Desirable: <150
Borderline: 150 to 199
High Risk: 200 to 499
HDL Cholesterol
Desirable: 60
Borderline: 35 to 45
High Risk: <35
LDL cholesterol
Desirable: 60 to 130
Borderline: 130 to 159
High Risk: 160 to 189
BEFORE initiating a STATIN
- Get baseline aminotransferase levels
- In the presence of liver disease:
- Pravastatin and Rosuvastatin are preferred
- Alcohol abstinence is imperative
- Start at a very low statin dose and titrate based on aminotransferase levels
- Re-evaluate in 4 to 12 weeks and re-check aminotransferase levels
- In the presence of liver disease:
- Check thyroid function (TSH)
- Hypothyroidism is a potential cause for dyslipidemia and can make patients more susceptible to muscle injury
Muscle Injury associated with statin use
- Risk is highest with statins extensively metabolized by the cytochrome P450 3A4
- Risk is highest with statins extensively metabolized by the cytochrome P450 3A4
- Examples: Lovastatin, Simvastatin, Atorvastatin
- If muscle injury occurs:
- STOP statin
- Evaluate for potential contributing factors
- Hypothyroidism
- Vitamin D Deficiency
- Medication interactions
- Treatment options:
- Restart at lower dose
- Attempt alternate day dosing
- Switch statin agents
- Switch to non-statin cholesterol lowering agent.
Hypertriglyceridemia (HTG)
- Associated with an increased risk for cardiovascular events and acute pancreatitis
- Occurs in approximately 25% of adults in the USA
Triglyceride Levels:
- Normal: < 150 mg/dL
- Moderate: 150 to 499 mg/dL
- Severe: 500 to 999 mg/dL
Risk factors:
- Insulin resistance, renal disease, hypothyroidism, diet with excess caloric intake, daily alcohol consumption, pregnancy, multiple myeloma, lupus and medications
- Medications: Thiazide diuretics, glucocorticoids, antivirals, second generation antipsychotics, beta blockers
Presentation:
- Generally asymptomatic, however some with moderate to severe HTG experience xanthomas
Hypertriglyceridemia Treatment
General measures:
- Address modifiable causes
- Uncontrolled diabetes
- Hypertension management
- Improve nutrition and restrict alcohol intake
- Smoking cessation
- Treat dyslipidemia
Moderate HTG (150 to 499)
- High ASCVD risk
- Marine omega-3 fatty acid therapy (Icosapent ethyl)
- Without high risk for ASCVD
- General measure
Moderate to Severe HTG (500 to 999)
- High ASCVD ethyl
- Icosapent ethyl
- If unsuccessful, add a vibrate
- Without high risk for ASCVD
- Fibrat therapy
- If unsuccessful, add on omega-3 fatty acid
Severe HTG (>1000)
- Extreme dietary fat restriction, alcohol abstinence, fibrate
High ASCVD risk
Established ASCVD or diabetes mellitus PLUS two additional ASCVD risk factors
- Age >50 years, cigarette smoking, hypertension, HDL-C <40 for males or <50 for females, C-reactive protein >4, CrCl <60, retinopathy, micro or macroalbuminuria and ankle brachial index 0.9